Aerial BioPharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aerial BioPharma - overview
Established
2011
Location
Morrisville, NC, US
Primary Industry
Pharmaceuticals
About
Aerial BioPharma is a biotechnology firm specializing in sustainable agricultural solutions, focusing on biological products designed to enhance soil health and crop resilience, thereby promoting agricultural productivity. Founded in 2011 in Morrisville, US, Aerial BioPharma develops innovative agricultural solutions. It was acquired by JAZZ PHARMACEUTICALS in January 2014, with financial details undisclosed. The company has received a total of USD 1.
70 mn across its funding rounds, with the latest funding occurring in 2014. The CEO of Aerial BioPharma is Moise Khayrallah, who plays a pivotal role in the company's strategic direction. Aerial BioPharma specializes in innovative biotechnology solutions that enhance agricultural productivity and sustainability. The company’s primary offerings include advanced biological products that improve soil health and crop resilience against environmental stresses.
Their products are designed to harness natural biological processes, promoting increased plant growth and yield potential. Aerial BioPharma serves clients ranging from farmers to agribusinesses across North America, Europe, and select regions in Asia, addressing challenges like soil degradation and climate variability while supporting sustainable farming practices. Aerial BioPharma generates revenue through a business model focused on direct-to-consumer sales and partnerships with agricultural distributors. Their offerings include tailored pricing plans for bulk purchases and subscription services for recurring deliveries of biological products.
Transaction structures typically involve agreements with agricultural retailers, ensuring clients have seamless access to Aerial BioPharma's solutions. This structured approach fosters client loyalty and facilitates consistent revenue streams through ongoing relationships and product support services. Aerial BioPharma aims to expand its product line by developing new biological solutions to address emerging agricultural challenges. The company is targeting expansion into additional markets in Europe and Asia by the end of 2025.
Funding received in 2014 is expected to support these initiatives, enabling the launch of new products and the establishment of strategic partnerships to enhance market penetration.
Current Investors
3G Capital, Rex Health Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Drug Stores/Convenience Stores, Pharmaceutical Research & Development
Website
www.aerialbio.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.